Bracco and Health Trust in contrast media deal

Bracco Diagnostics, the US-based subsidiary of Italy's Bracco Imaging SpA, and HealthTrust Purchasing Group, a health care group purchasing organizations in the USA, have announced a three-year agreement, to make Bracco's Magnetic Resonance Imaging contrast media products available to HealthTrust members through 2010.

This agreement includes MultiHance (gadobenate dimeglumine) injection, 52mg/mL and ProHance (gadoteridol) injection 279.3mg/mL.

"We are very excited to expand our partnership with HealthTrust to include our MR portfolio. This agreement provides HealthTrust members access to high quality MR contrast media," said Carlo Medici, chief executive of Bracco Diagnostics.